Holen Sie sich die Stockscreener-App
1.00
4.31%
-0.04
Handel nachbörslich:
.96
-0.04
-4.00%
Maxcyte Inc Aktie (MXCT) Neueste Nachrichten
MaxCyte outlines $30M-$32M 2026 revenue outlook as board authorizes $10M share repurchase program - MSN
MaxCyte Inc. (MXCT) Struggles Near Support as Selling Pressure PersistsFree Signal Network - Newser
MaxCyte (MXCT) Q1 2026 Earnings: Narrower Loss Beats Estimates, Stock DeclinesSegment Revenue Breakdown - Newser
MaxCyte Inc stock (US57777K1060): cell-therapy enabler after recent earnings update - AD HOC NEWS
MaxCyte, Inc. (MXCT) reports Q1 loss, tops revenue estimates - MSN
MaxCyte Inc stock (US57777K1060): recent volatility and growth hopes in cell therapy tools - AD HOC NEWS
MaxCyte Q1 earnings call highlights - MSN
What MaxCyte (MXCT)'s -4.59% Decline Means for Investors 2026-05-15Stock Idea Sharing Hub - newser.com
MaxCyte (MXCT) Reports Strong Q1 2026 — Revenue $N/A, EPS BeatsExpert Entry Points - newser.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ibio (IBIO), MaxCyte (MXCT) and Atea Pharmaceuticals (AVIR) - The Globe and Mail
River Global Investors Discloses Investment in MaxCyte with 6.1% Stake - TradingView
River Global Investors builds 6.1% MaxCyte (MXCT) position with 6.53M shares - Stock Titan
Stock Market Today: Dow Jones Futures Fall, S&P 500 Gains As Trump Takes Big Tech Leaders To China—Nvidia, Nextpower, Red Cat In Focus - Sahm
Cisco, Alibaba And 3 Stocks To Watch Heading Into Wednesday - Sahm
MaxCyte (MXCT) EPS Loss Narrows In Q1 2026 Challenging Bearish Profitability Narratives - Sahm
MSN Money - MSN
MaxCyte (NASDAQ: MXCT) Q1 2026 revenue dips as expenses fall - Stock Titan
Stifel Maintains MaxCyte(MXCT.US) With Buy Rating, Maintains Target Price $4 - Moomoo
BTIG Maintains MaxCyte(MXCT.US) With Hold Rating - Moomoo
MaxCyte posts $4.8M loss, still lines up $10M stock buyback - Stock Titan
Stock Market Today: Dow Jones Futures Fall, Nasdaq Gains As Trump Takes Big Tech Leaders To China— Nvidia, Nextpower, Red Cat In Focus (UPDATED) - Benzinga
MaxCyte, Inc. (NASDAQ:MXCT) Q1 2026 Earnings Call Transcript - Insider Monkey
Minot Light Capital Partners Q1 2026 Investor Letter - HarianBasis.co
Here’s Why MaxCyte (MXCT) is Becoming a High-Conviction Bet for Investors - Insider Monkey
Earnings Call Summary | MaxCyte(MXCT.US) Q1 2026 Earnings Conference - Moomoo
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance - The Manila Times
MaxCyte Q1 Earnings Call Highlights - sharewise.com
MaxCyte, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: MaxCyte beats Q1 2026 forecasts with strong revenue By Investing.com - Investing.com South Africa
Earnings call transcript: MaxCyte beats Q1 2026 forecasts with strong revenue - Investing.com Nigeria
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
MaxCyte Reports Q1 2026 Results, Launches Share Buyback - TipRanks
MaxCyte (NASDAQ:MXCT) Q1 2026 Results Beat Estimates, Stock Rises on Buyback - ChartMill
MaxCyte (NASDAQ: MXCT) Q1 2026 revenue $9.7M as board approves $10M buyback - Stock Titan
Press Release: MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance - Moomoo
MaxCyte Inc (MXCT) Q1 2026 Earnings Call Highlights: Revenue Meets Expectations Amid Core ... By GuruFocus - Investing.com Canada
MaxCyte (MXCT) price target decreased by 11.67% to 4.33 - MSN
BTIG Downgrades MaxCyte (MXCT) - MSN
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026 - The Manila Times
MaxCyte (MXCT) price target decreased by 14.88% to 4.90 - MSN
1.35%
2.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):